LTIP888A - Polyethylene glycol -interferon conjugates - Google Patents

Polyethylene glycol -interferon conjugates

Info

Publication number
LTIP888A
LTIP888A LTIP888A LTIP888A LTIP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A
Authority
LT
Lithuania
Prior art keywords
polyethylene glycol
interferon conjugates
conjugates
interferon
production
Prior art date
Application number
LTIP888A
Other languages
Lithuanian (lt)
Inventor
Robert Karasiewicz
Carlo Nalin
Perry Rosen
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LTIP888A publication Critical patent/LTIP888A/en
Publication of LT3174B publication Critical patent/LT3174B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Šiame išradime aprašomi fiziologiškai aktyvūs, tirpūs vandenyje polietilenglikolio konjungtai su interferonu ir nauji polietilenglikolio junginiai, kurie gali būti panaudoti konjugatų gamybai.The present invention describes physiologically active, water-soluble polyethylene glycol conjugated to interferon and novel polyethylene glycol compounds that may be used in the production of conjugates.

LTIP888A 1992-08-26 1993-08-25 Polyethylene glycol -interferon conjugates LT3174B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Publications (2)

Publication Number Publication Date
LTIP888A true LTIP888A (en) 1994-08-25
LT3174B LT3174B (en) 1995-02-27

Family

ID=25467637

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP888A LT3174B (en) 1992-08-26 1993-08-25 Polyethylene glycol -interferon conjugates

Country Status (37)

Country Link
US (1) US5382657A (en)
EP (1) EP0593868B1 (en)
JP (1) JP2859105B2 (en)
KR (1) KR100295520B1 (en)
CN (3) CN1183112C (en)
AT (1) ATE165102T1 (en)
AU (1) AU668742B2 (en)
BG (1) BG98067A (en)
BR (1) BR9303469A (en)
CA (1) CA2103829C (en)
CZ (1) CZ169393A3 (en)
DE (1) DE69317979T2 (en)
DK (1) DK0593868T3 (en)
EE (1) EE9400151A (en)
ES (1) ES2116376T3 (en)
FI (1) FI109765B (en)
HR (1) HRP931094A2 (en)
HU (1) HUT67013A (en)
IL (1) IL106750A0 (en)
IS (1) IS4067A (en)
LT (1) LT3174B (en)
LV (1) LV10907B (en)
MW (1) MW7693A1 (en)
MX (1) MX9305146A (en)
MY (1) MY131445A (en)
NO (1) NO933028D0 (en)
NZ (2) NZ264872A (en)
OA (1) OA09850A (en)
PH (1) PH30460A (en)
PL (1) PL300194A1 (en)
RO (1) RO112730B1 (en)
SI (1) SI9300423A (en)
SK (1) SK89893A3 (en)
UY (1) UY23635A1 (en)
YU (1) YU56693A (en)
ZA (1) ZA936098B (en)
ZW (1) ZW11193A1 (en)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2989002B2 (en) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
EP0393438B1 (en) * 1989-04-21 2005-02-16 Amgen Inc. TNF-receptor, TNF-binding protein and DNA coding therefor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
NZ276943A (en) * 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
ATE203415T1 (en) * 1994-02-08 2001-08-15 Amgen Inc ORAL ADMINISTRATION SYSTEM OF CHEMICALLY MODIFIED PROTEINS G-CSF
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (en) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Conjugate for the treatment of infectious, autoimmune and skin diseases
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (en) 1995-11-02 2004-09-16 Schering Corporation CONTINUOUS INFUSION THERAPY OF CITOCINES AT LOW DOSE.
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
DE69838552T2 (en) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2001516725A (en) * 1997-09-18 2001-10-02 エフ．ホフマン−ラ ロシュ アーゲー Use of IFN-α and amantadine for the treatment of chronic hepatitis C hepatitis
AU1825299A (en) 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (en) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med LIPOPEPTIDES CONTAINING A FRAGMENT OF THE INTERFERON GAMMA, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
BR9909087A (en) * 1998-03-26 2000-12-05 Schering Corp Formulations for protection of peg-alpha interferon conjugates
AU762621B2 (en) * 1998-04-28 2003-07-03 Merck Serono Sa Polyol-IFN-beta conjugates
MY129244A (en) 1998-05-15 2007-03-30 Schering Corp Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
ITMI981148A1 (en) * 1998-05-22 1999-11-22 Therapicon Srl USE OF MODIFIED LYSOZYME C TO PREPARE MEDICINE COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES
NZ508249A (en) * 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
JP2002518354A (en) * 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ Glycosulfate peptides, their synthesis and use
HK1042434B (en) * 1998-10-16 2008-01-25 生物基因Ma公司 Polymer conjugates of interferon beta-1a and uses
CN100480266C (en) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 Interferon-beta fusion protein and use
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE526401T1 (en) 1999-01-14 2011-10-15 Bolder Biotechnology Inc METHOD FOR PRODUCING PROTEINS WITH FREE CYSTEINE RESIDUE
CN1376164A (en) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 GCSF conjugates
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
HU230057B1 (en) 1999-04-08 2015-06-29 Merck Sharp & Dohme Corp. Melanoma therapy
PE20010288A1 (en) 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES
WO2001004304A1 (en) 1999-07-07 2001-01-18 Zymogenetics, Inc. Human cytokine receptor
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
CA2387205A1 (en) 1999-10-12 2001-04-19 Santen Pharmaceutical Co., Ltd. Interferon complex and pharmaceutical use thereof
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
KR20020065517A (en) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 Interferon gamma conjugates
EP1229924A4 (en) 1999-11-19 2004-12-15 Univ Leland Stanford Junior TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES THEREFORE
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2001040467A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
CZ20022727A3 (en) 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptide conjugate, process of its preparation and pharmaceutical preparation
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1251866A1 (en) * 2000-01-24 2002-10-30 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
CN100488562C (en) 2000-02-11 2009-05-20 拜耳医药保健有限公司 Coagulation factor VII or VIIa-like molecules
KR100353392B1 (en) * 2000-03-13 2002-09-18 선바이오(주) Method of Preparing the PEG-Protein Composition Having Enhanced Biological Activity
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US20040082765A1 (en) * 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
WO2002038766A2 (en) 2000-11-07 2002-05-16 Zymogenetics, Inc. Human tumor necrosis factor receptor
AU2002251988A1 (en) * 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
BR0207576A (en) 2001-02-27 2004-04-27 Maxygen Aps Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
AU2002305944A1 (en) 2001-03-02 2002-09-19 Zymogenetics, Inc. Mouse cytokine receptor
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2002083166A1 (en) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Interferon-polymer complexes and medicinal use thereof
WO2003000278A1 (en) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Ointments
MD2053C2 (en) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remedy with interferon inducing action
DE60223047T2 (en) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal PROCESS FOR PREPARING ACTIVATED POLYETHYLENE GLYCOLS
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR100888371B1 (en) 2002-01-17 2009-03-13 동아제약주식회사 Antiviral agent including branched polymer derivative and interferon conjugate
SI3025726T1 (en) * 2002-01-18 2020-03-31 Biogen Ma Inc. Polyalkylene polymer compounds and their use
EP1496076B1 (en) * 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
WO2003087308A2 (en) * 2002-04-11 2003-10-23 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
ES2356307T3 (en) 2002-04-19 2011-04-06 Zymogenetics, L.L.C. PROCEDURES TO DETECT OR MODULATE THE INTERACTION OF A CITOCINE RECEIVER WITH ITS BINDING.
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
CA2491178A1 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004012773A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
MXPA05002477A (en) * 2002-09-05 2005-10-19 Gen Hospital Corp Asialo-interferons and the treatment of liver cancer.
MXPA05002476A (en) * 2002-09-05 2005-10-19 Gi Company Inc Modified asialo-interferons and uses thereof.
CA2498062C (en) * 2002-09-27 2010-05-25 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol)
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
BRPI0407511A (en) * 2003-02-19 2006-02-14 Pharmacia Corp activated polyethylene glycol esters
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
ES2303132T3 (en) 2003-08-07 2008-08-01 Zymogenetics, Inc. HOMOGENEAS PREPARATIONS OF IL-29.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007533298A (en) 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Derivatives of IL-21
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
ES2428358T3 (en) 2003-10-17 2013-11-07 Novo Nordisk A/S Combination therapy
US20050089952A1 (en) * 2003-10-22 2005-04-28 Akzo Nobel N.V. Apparatuses and processes for increasing protein PEGylation reaction yields
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) * 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) * 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
BRPI0511196A (en) * 2004-05-19 2007-12-04 Maxygen Inc isolated or recombinant polypeptide, conjugate, composition, host cell, vector, methods for making a polypeptide, for making a conjugate, for reducing the copy number of a virus in virus-infected cells, for reducing the level of rna hcv, dna hbv and rna hiv in the serum of a patient infected with hcv, hbv and hiv, and use of the polypeptide, conjugate or composition
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
MX2007000728A (en) * 2004-07-21 2007-03-15 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
MX2007001663A (en) 2004-08-12 2007-04-10 Schering Corp Stable pegylated interferon formulation.
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
KR101224781B1 (en) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2005319518B2 (en) * 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CA2607291A1 (en) 2005-05-12 2006-11-23 Steven D. Levin Compositions and methods for modulating immune responses
JP2008545393A (en) * 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド Advanced interferon alpha polypeptide
US20100135959A1 (en) * 2005-06-03 2010-06-03 Ambrx, Inc. Human Interferon Molecules and Their Uses
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ATE524183T1 (en) 2005-06-17 2011-09-15 Novartis Ag USE OF SANGLIFEHRIN IN HCV THERAPY
EP1901777A2 (en) * 2005-06-20 2008-03-26 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
EA014157B1 (en) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
EA019888B1 (en) 2005-07-25 2014-07-30 Интермьюн, Инк. Intermediate compound for making macrocyclic inhibitors of hepatitis c virus replication and method of synthesis thereof
EP1937824B1 (en) * 2005-08-18 2013-03-13 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
KR20080056241A (en) 2005-09-28 2008-06-20 지모제넥틱스, 인코포레이티드 IL-17A and IL-17F antagonists and methods of use thereof
ATE493409T1 (en) 2005-10-11 2011-01-15 Intermune Inc COMPOUNDS AND METHODS FOR INHIBITING HEPATITIS C VIRUS REPLICATION
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
JP2009514814A (en) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション Glycosylated and glycosylated poultry-derived therapeutic proteins
CA2625540C (en) * 2005-11-08 2017-03-21 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
WO2007059312A2 (en) * 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
KR101418607B1 (en) 2006-01-12 2014-07-14 호쿠산 가부시키가이샤 Oral composition containing interferon-α
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor and application thereof
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
RU2448976C2 (en) 2006-04-11 2012-04-27 Новартис Аг Hcv/hiv inhibitors and their application
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (en) * 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
BRPI0712008A2 (en) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag extended fix derivatives and analogs
CN101336110B (en) 2006-06-01 2011-06-01 程云 Peptides and their derivatives for preventing or treating liver damage and applications thereof
CN1911447B (en) * 2006-06-30 2010-05-12 复旦大学 Transferrin-polyethylene glycol-drug molecule complex and its application for preparing medicine
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
PT2064333E (en) * 2006-09-08 2014-06-09 Ambrx Inc Suppressor trna transcription in vertebrate cells
EP2061878B1 (en) * 2006-09-08 2014-01-08 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
CN106008699A (en) 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
JP5537946B2 (en) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
HRP20120522T1 (en) 2007-03-30 2012-08-31 Ambrx Modified fgf-21 polypeptides and their uses
CN103965347B (en) * 2007-05-02 2017-07-18 Ambrx公司 Modified interferon beta polypeptides and its purposes
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
DK2196475T3 (en) 2007-09-04 2012-09-17 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a modified with polyethylene glycol, method of synthesis thereof and use thereof
ES2908934T3 (en) 2007-10-04 2022-05-04 Zymogenetics Inc B7 Family Member ZB7H6 and Related Compositions and Methods
CN101918579A (en) 2007-10-22 2010-12-15 先灵公司 Fully human anti-VEGF antibodies and methods of use
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
EP2215120A2 (en) 2007-12-07 2010-08-11 ZymoGenetics, Inc. Humanized antibody molecules specific for il-31
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
BRPI0822530B1 (en) 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Method of preparing a polyethylene glycolated human growth hormone (peg-modified), peg-modified human growth hormone of lower apparent molecular weight and its use, preparation of peg-modified human growth hormone of lower apparent molecular weight and its method of preparation and composition
AR071874A1 (en) 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
JP2011526154A (en) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド Soluble hybrid Fcγ receptor and related methods
PT2318029T (en) * 2008-07-23 2018-01-10 Ambrx Inc MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR UTILIZATIONS
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
MX2011003196A (en) 2008-09-26 2011-04-27 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
EP2341924A4 (en) 2008-10-02 2013-01-23 David Gladstone Inst METHODS OF TREATING HEPATITIS C VIRUS INFECTION
CN102448458B (en) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 Methods and compositions for treating viral infections of the Flaviviridae family
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2896404B1 (en) 2009-06-04 2017-08-02 Novartis AG Methods for identification of sites for IgG conjugation
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED PORCINE GROWTH HORMONE POLYPEPTIDES AND USES THEREOF
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
EP2585065A1 (en) 2010-06-24 2013-05-01 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
MX2013003903A (en) 2010-10-05 2013-05-20 Novartis Ag New treatments of hepatitis c virus infection.
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
RU2013129824A (en) 2010-11-30 2015-01-10 Новартис Аг NEW TREATMENT OF HEPATITIS C VIRUS INFECTION
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
JP2014509628A (en) 2011-03-31 2014-04-21 ノバルティス アーゲー Alice polyvir for treating hepatitis C virus infection
PL2694087T3 (en) 2011-04-01 2015-06-30 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
KR20140011379A (en) 2011-04-13 2014-01-28 노파르티스 아게 Treatment of hepatitis c virus infection with alisporivir
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2709648A4 (en) 2011-05-19 2015-04-08 Geysen Hendrik M Compounds that bind to the erythropoietin receptor
CN103930440A (en) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 Relaxin fusion polypeptide and use thereof
EP2734640A1 (en) 2011-07-20 2014-05-28 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for determining treatment response in patients infected with hcv genotype 4
WO2013028233A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Peg-interferon lambda 1 conjugates
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
AU2012314517A1 (en) 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
CN104053670A (en) 2011-10-31 2014-09-17 百时美施贵宝公司 Fibronectin binding domains with reduced immunogenicity
BR112014013649A2 (en) 2011-12-06 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University methods and agents for the treatment of viral diseases and uses of said agents
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc Phosphate esters of noribogaine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
CA2868883C (en) 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
HUE043552T2 (en) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6429771B2 (en) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen binding protein that binds to c-Met
CA2877814A1 (en) 2012-06-22 2013-12-27 Dingqiu HUANG Antigen binding proteins that bind ccr2
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
PL3137078T3 (en) 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
DK3180018T3 (en) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistic tumor treatment with IL-2 and integrin-binding Fc fusion protein
JP2017529331A (en) 2014-08-22 2017-10-05 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen-binding protein that binds to CXCR3
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
SMT202100388T1 (en) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
FI3215193T3 (en) * 2014-11-06 2023-12-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
CN107532146A (en) * 2015-03-17 2018-01-02 国立大学法人信州大学 The method that BMDC is prepared by using IFN non-adherent culture
DK3285768T3 (en) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS INCLUDING LONAFARNIB AND RITONAVIR
AU2016349685A1 (en) 2015-11-03 2018-03-15 F. Hoffmann-La Roche Ag Combination therapy of an HBV capsid assembly inhibitor and an interferon
ES2844629T3 (en) 2015-11-04 2021-07-22 Eiger Biopharmaceuticals Inc Treatment of hepatitis delta virus infection
BR112018015480A2 (en) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. pd-l1-binding antigen binding proteins
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
CA3049656A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
JP7189399B2 (en) 2017-01-18 2022-12-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of patients suffering from myeloproliferative disorders
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
US20210285000A1 (en) 2020-03-05 2021-09-16 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
JP2023531682A (en) 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Compositions and methods for treatment of hepatitis D virus infection
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
CN120676956A (en) 2023-02-09 2025-09-19 谢彦晖 Polyethylene glycol modified interleukin 2, glucocorticoid and hyaluronic acid for treating atopic dermatitis
AU2024308069A1 (en) 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (en) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (en) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (en) * 1969-12-02 1971-04-16 Baxter Laboratories Inc STREPTOKINASE CHEMICALLY LINKED TO A CARBOHYDRATE MATRIX (
DE2247163A1 (en) * 1972-09-26 1974-03-28 Merck Patent Gmbh CARRIER MATRIX FOR FIXING BIOLOGICALLY ACTIVE SUBSTANCES AND THE PROCESS FOR THEIR PRODUCTION
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (en) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Purification of lpf-ha
JPS60127952A (en) 1983-12-14 1985-07-08 Fanuc Ltd Regional work
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (en) * 1989-04-19 2006-03-01 Enzon, Inc. A PROCESS TO FORM A MODIFIED POLYPEPTIDE THAT INCLUDES A POLYPEPTIDE AND A POLYCHYLENE OXIDE.
EP0400472B1 (en) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
JP2978187B2 (en) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 Method for producing modified superoxide dismutase
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
JP3187044B2 (en) * 1989-12-01 2001-07-11 ビーエーエスエフ アクチェンゲゼルシャフト Hirudin mutein and hirudin polyalkylene glycol complex
JPH04202293A (en) * 1990-11-29 1992-07-23 Tonen Corp Working fluid
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
EP0593868B1 (en) 1998-04-15
ZA936098B (en) 1994-03-01
NO933028D0 (en) 1993-08-25
HUT67013A (en) 1995-01-30
IS4067A (en) 1994-02-27
SK89893A3 (en) 1994-04-06
LT3174B (en) 1995-02-27
ZW11193A1 (en) 1994-03-23
ATE165102T1 (en) 1998-05-15
OA09850A (en) 1994-08-15
MX9305146A (en) 1994-03-31
EP0593868A1 (en) 1994-04-27
YU56693A (en) 1997-01-08
CN1155618C (en) 2004-06-30
BR9303469A (en) 1994-03-22
PL300194A1 (en) 1994-04-05
RO112730B1 (en) 1997-12-30
DK0593868T3 (en) 1999-02-08
MW7693A1 (en) 1994-06-08
CZ169393A3 (en) 1994-04-13
LV10907B (en) 1996-04-20
UY23635A1 (en) 1994-03-01
CA2103829C (en) 2003-04-08
CN1183112C (en) 2005-01-05
KR940003969A (en) 1994-03-14
HU9302366D0 (en) 1993-11-29
ES2116376T3 (en) 1998-07-16
CA2103829A1 (en) 1994-02-27
AU668742B2 (en) 1996-05-16
CN1088936A (en) 1994-07-06
FI109765B (en) 2002-10-15
JP2859105B2 (en) 1999-02-17
BG98067A (en) 1994-12-02
MY131445A (en) 2007-08-30
DE69317979D1 (en) 1998-05-20
CN1039015C (en) 1998-07-08
JPH06192300A (en) 1994-07-12
FI933740A0 (en) 1993-08-25
SI9300423A (en) 1994-03-31
HRP931094A2 (en) 1997-06-30
CN1211578A (en) 1999-03-24
PH30460A (en) 1997-05-28
EE9400151A (en) 1996-02-15
AU4478093A (en) 1994-03-03
NZ248452A (en) 1995-12-21
LV10907A (en) 1995-12-20
DE69317979T2 (en) 1998-08-20
IL106750A0 (en) 1993-12-08
CN1173500A (en) 1998-02-18
US5382657A (en) 1995-01-17
FI933740L (en) 1994-02-27
NZ264872A (en) 1996-01-26
KR100295520B1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
LTIP888A (en) Polyethylene glycol -interferon conjugates
FI964681A0 (en) Lactobacillus strains of human origin, their compositions and their uses
DE69531204D1 (en) FACTOR IX FORMULATIONS
DE69130381D1 (en) Oligomers, their uses and formulations
YU15499A (en) Olanzapine dihydrate d
FI955315L (en) HIV protease inhibitors useful in the treatment of AIDS
DE69112837D1 (en) WATER-SOLUBLE PENTACYCLIC TRITERPEN MIXTURE AND THEIR PRODUCTION.
ATE203519T1 (en) QUINOLINE DERIVATIVES AS ANTIMALARIATIC AGENTS
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
NO964238L (en) Halofantrine-free base for the treatment of malaria and mixtures
ATE234636T1 (en) CONJUGATE COMPRISING AN ACTIVE INGREDIENT, A POLYPEPTIDE AND A POLYETHER
HUP9902415A2 (en) Solid instant-release forms of administration and process for producing the same
BG100248A (en) SQUALENSENTEZA INHIBITORS
MD970269A (en) Clavulanates
FR2652742B1 (en) COSMETIC AND DERMO-PHARMACEUTICAL ANALLERGIC COMPOSITIONS.
IT9048066A0 (en) 2- 6, 7-SUSTITUTED AMINOTETRALINES ACTIVE AS IMMUNOMODULANTS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IT1264546B1 (en) PHARMACEUTICAL COMPOSITION WITH ANTI-ACID ACTIVITY IN THE FORM OF A SUCRALFATE GEL-BASED SUSPENSION
IT1254452B (en) N-OXIDES AND N, N'-DIOXIDES OF 3- (PIPERAZIN-1-IL) -PROPAN-1,2-DIOLS
ATE167539T1 (en) DEVICE FOR CONNECTING TWO PROFILES AND MALE AND/OR FEMALE PROFILES
RU93050376A (en) POLYETHYLENE GLYCOL INTERFERON COMPOUNDS
AU132015S (en) Pants
AU103662S (en) Trousers
AU114105S (en) Washbasin
GT199200058A (en) PROTEIN CONJUGATES WITH POLYETHYLENE GLYCOL
SV1990000045A (en) PREPARATION OF CYCLLOALCAN [B] DEHYDROINDOL E-INOSULFONAMIDES SUBSTITUTED, REF. LE A 27 157-SV.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 19970825